A Year Of Surprises Shakes Up Off-Patent Industry
Sandoz, Mylan And Teva Switch Places At The Top
Executive Summary
After an eventful year for the off-patent industry, the world’s leading generics and biosimilars players have switched places in Generics Bulletin’s newly compiled global sales ranking.
You may also be interested in...
Pfizer To Merge Off-Patent Business With Mylan
Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.
Beximco Takes Control Of Sanofi Bangladesh
Beximco has struck a deal worth nearly $50m to acquire a majority stake in Sanofi Bangladesh, allowing the firm to expand in its domestic market.
Diversified Sourcing And Sustainability Are Key For Centrient
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.
Need a specific report? 1000+ reports available
Buy Reports